Shingles is “one of the worst pains in medicine.” A vaccine is highly effective at preventing it, but many people don’t get ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
Dr. Pham Thi My Lien, president of GSK Vietnam, spoke with VIR’s Bich Thuy about the importance of adult vaccinations, one of ...
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
More than 200,000 Australians who are immunocompromised will gain free access to the shingles vaccine in an expansion of a ...
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
Shingles is a painful, blistering rash caused by the reactivation of the varicella-zoster virus (VZV)—the same virus that causes chickenpox. An estimated one million people develop shingles ...
GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback